RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer

The FDA approved RYBREVANT in combination with chemotherapy for EGFR-mutated NSCLC patients. Results from the Phase 3 MARIPOSA-2 study showed improved outcomes, making it the third new indication for RYBREVANT this year.